Aperta Biosciences is an emerging biopharma company focused on developing novel therapeutics for Ocular Surface Disease (OSD), specifically blepharitis and other related conditions. With a team of experienced executives and specialists in ophthalmic indications, Aperta Biosciences is dedicated to bringing effective treatments to those suffering from OSD. Blepharitis, a common and uncomfortable condition, is characterized by inflammation of the eyelid margins.

If left untreated, it can lead to severe infection, vision impairment, and even permanent alterations to the eyelid. Aperta Biosciences recognizes the role of Demodex mites in blepharitis, as uncontrolled infestations of these mites drive the disease progression. By directly targeting and eliminating Demodex infestations, Aperta Biosciences aims to address the underlying cause of blepharitis.

Aperta Biosciences' lead program, APT-001, is a patent-pending ophthalmic suspension that represents a new treatment approach to blepharitis. This innovative solution directly eradicates ocular demodicosis, providing relief and long-term improvement for those suffering from blepharitis. Trust in Aperta Biosciences to deliver pioneering therapies that offer a clear vision for a healthier ocular surface